Skip to main content
SpringerLink
Log in
Book cover

Therapiekonzepte Onkologie pp 844–869Cite as

Hodentumoren

  • Chapter

Zusammenfassung

Wichtigste Unterscheidung in Seminom (spermatozytär, klassisch) und Nichtseminom (embryonales Karzinom, Dottersacktumor, Chorionkarzinom, reifes und unreifes Teratom, selten: Polyembryom, Teratom mit malignen Veränderungen) — Einteilung nach WHO [8]. Histopathologische Malignitätsgrade werdrn nicht unterschieden. Frühform: Carcinoma in situ (Cis) bzw. Testikuläre intraepitheliale Neoplasie (TIN); in 5% der Fälle bei Diagnose im kontralateralen Hoden vorhanden [9,10].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Pottern LM, Goedert JJ (1986) Epidemiology of Testicular Cancer. In: Javadpour N (ed) Principles and Management of Testicular Cancer. Thieme, New York, pp 108–119

    Google Scholar 

  2. Senturia YD (1987) The Epidemiology of Testicular Cancer. Br J Urol 60: 285–291

    Article  PubMed  CAS  Google Scholar 

  3. Osterlind A (1986) Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943–1982. Br J Cancer 53: 501

    Article  PubMed  CAS  Google Scholar 

  4. Heimdal K, Fossa SD, Johansen A (1990) Increasing incidence and changing stage distribution of testicular carcinoma in Norway 1970–1987. Br J Cancer 62: 277–278

    Article  PubMed  CAS  Google Scholar 

  5. Levi F, Te VC, La Vecchia C (1990) Testicular cancer trends in the Canton of Vaud, Switzerland, 1974–1987. Br J Cancer 62: 871–873

    Article  PubMed  CAS  Google Scholar 

  6. Sommerhoff CH (1982) Altersverteilung. In: Weißbach L, Hildenbrand G (Hrsg) (1991) Register und Verbund-Studie für Hodentumoren — Bonn. Ergebnisse einer prospektiven Untersuchung. Zuckschwert, München, S 209–214

    Google Scholar 

  7. Forman D, Gallagher R, Moller H et al. (1990) Aetiology and epidemiology of testicular cancer: report of consensus group. In: Newling DWW and Jones WG (Hrsg) Prostate cancer and testicular cancer. Wiley-Liss Inc, New York, S 245–253

    Google Scholar 

  8. Mostofi FK, Sobin LH (1977) Histological typing of testis tumours. International Histologial Classification of Tumours, No 16. WHO Genf

    Google Scholar 

  9. Von der Maase H (1991) Diagnosis and management of carcinoma in situ of the testis. In: Horwich A (ed) Testicular cancer. Investigation and management. Chapman & Hall Medical, London-New York, pp 319–330

    Google Scholar 

  10. Dieckmann KP, Loy V, Huland H (1989) Das Carcinoma in situ des Hodens: Klinische Bedeutung, Diagnostik und Therapie. Urologe A 28: 271–280

    Google Scholar 

  11. Einhorn LH (1987) Treatment strategies of testicular cancer in the Unites States. In: Rorth M, Daugaard G, Skakkebaek NE et al. (eds) Carcinoma in situ and Cancer of the Testis. Blackwell Scientific Publ, Oxford, pp 399–405

    Google Scholar 

  12. UICC (1992) TNM Klassifikation maligner Tumoren. Hermanek P, Scheibe O, Spiessl B, Wagner G (Hrsg) Springer-Verlag Berlin, 4. Auflage, 2. Revision

    Google Scholar 

  13. Hartlapp HJ, Weißbach L (1982) Zur Notwendigkeit der Unterteilung des Stadium II bei Hodentumoren. In: Illiger HJ, Sack H, Seeber S, Weißbach L (Hrsg) Nichtseminomatöse Hodentumoren. Beiträge zur Onkologie 8, Karger, Basel, S72–75

    Google Scholar 

  14. Bosl GJ, Geller NL, Cirrincione C et al. (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403–3407

    PubMed  CAS  Google Scholar 

  15. Cavalli F, Monfardini S, Pizzocaro G (1980) Report on the international workshop on staging and treatment of testicular cancer. Eur J Cancer 16: 1367–1372

    PubMed  CAS  Google Scholar 

  16. Droz JP, Kramar A, Ghosn M et al. (1988) Prognostic factors in advanced nonseminomatous testicular cancer. Cancer 62: 564–568

    Article  PubMed  CAS  Google Scholar 

  17. Medical Research Council Working Party on Testicular Tumours (1985) Prognostic factors in advanced non-seminomatous germ-cell testicular tumours. Lancet ii: 8–11

    Google Scholar 

  18. Ozols RF, Ihde DC, Linehan WM et al. (1988) A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumors. J Clin Oncol 6: 1031–1040

    PubMed  CAS  Google Scholar 

  19. Scheulen ME, Niederle N, Pfeiffer R, Schmidt CG (1988) Prognostische Faktoren bei Patienten mit fortgeschrittenen nichtseminomatösen Hoden-Karzinomen. In: Schmoll HJ, Weißbach L (Hrsg) Diagnostik und Therapie von Hodentumoren. Springer, Berlin, S 96–110

    Google Scholar 

  20. Stoter G, Sylvester R, Sleijfer DT et al. (1987) Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res 47: 2714–2718

    PubMed  CAS  Google Scholar 

  21. Stoter G, Bosl GJ, Droz JP et al. (1990) Prognostic factors in metastatic germ cell tumours. In: Newling DW, Jones WG (eds) Prostate cancer and testicular cancer. Wiley-Liss Inc, New York, pp 313–319

    Google Scholar 

  22. Birch R, Williams S, Cone A et al. (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4: 400–407

    PubMed  CAS  Google Scholar 

  23. Weißbach L, Hildenbrand G (1984) Register und Verbundstudie für Hodentumoren. Ein Ergebnisbericht nach sieben Jahren. Z allg Med 60: 156–163

    Google Scholar 

  24. Droz JP, van Oosterom AT (1993) Treatment Options in Clinical Stage I Nonseminomatous Germ Cell Tumours of the Testis: A Wager on the Future? Eur J Cancer 26A: 1038–1044

    Article  Google Scholar 

  25. Stoter G, Sylvester R (1994) Prognostic Factors in Disseminated Non-Seminomatous Testicular Cancer. Proc ASCO 13:230 Abstract-No 705

    Google Scholar 

  26. Mead GM, Stenning SP (1994) Prognostic Factors for Metastatic Germ Cell Cancer Treated with Platinum-Based Chemotherapy: The International Germ Cell Cancer Collaborative Group project to Standardize Risk Criteria. Proc ASCO 13:251 Abstract-No 790

    Google Scholar 

  27. Bajorin DF, Mazumdar M, Motzer RJ, Vlamis V, Bosl GJ (1994) Model Comparisons Prediction Germ Cell Tumor Response to Chemotherapy. Proc ASCO 13, 232 Abstract-No 715

    Google Scholar 

  28. Heidenreich A, Stark L, Derschum W, Vietsch H von (1993) Die organerhaltende Therapie des bilateralen Hodentumors. Urologe A 32: 43

    PubMed  CAS  Google Scholar 

  29. Weißbach L (1993) Ist eine organerhaltende Operation des Hodentumors gerechtfertigt? Urologe A 32: 49

    PubMed  Google Scholar 

  30. Donohue JP (1990) Nerve-sparing retroperitoneal lymphadenectomy. In: Jaeger, Hartlapp JH (Hrsg) Aktueller Stand der Diagnostik und Therapie von Hodentumoren, Karger, Basel, S 195–204

    Google Scholar 

  31. Huland H, Dieckmann KP, Sauerwein D (1992) Nerverhaltende retroperitoneale Lymphadenektomie mit intraoperativer Elektrostimulation bei Patienten mit nichtseminomatösen Hodentumoren. Urologe A 31: 1–7

    PubMed  CAS  Google Scholar 

  32. Weißbach L, Boedefeld EA for the Testicular Tumor Study Group (1987) Localization of Solitary and Multiple Metastases in Stage II Nonseminomatous Testis Tumor as Basis for a Modified Staging Lymph Node Dissection in Stage I. J Urol 138: 77–82

    Google Scholar 

  33. Jaeger N, Weißbach L (1990) Indikation und Ausmaß der Salvage-Lymphadenektomie beim germinalen Hodentumor. Akt Urol 21: 57–63

    Article  Google Scholar 

  34. Fox EP, Einhorn LH, Weathers T et al. (1992) Outcome analysis for patients with persistent germ cell carcinoma in postchemotherapy retroperitoneal lymph node dissections. Proc Am Soc Clin Oncol 11: Abstract No 608

    Google Scholar 

  35. Bajorin DF, Herr H, Motzer RJ, Bosl GJ (1992) Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Sem Oncol 19: 148–158

    CAS  Google Scholar 

  36. Jäger N, van Ahlen H (1992) Die klinische Bedeutung der Marker AFP, HCG und LDH beim fortgeschrittenen Keimzelltumor. Urologe B 32: 21–23

    Google Scholar 

  37. Herr HW, Toner GC, Geller NL, Bosl GJ (1991) Patient Selection for Retroperitoneal Lymph Node Dissection after Chemotherapy for Nonseminomatous Germ Cell Tumors. Eur Urol 19: 1–5

    PubMed  CAS  Google Scholar 

  38. Fossa SD, Aass N, Ous S, Hole J, Stenwig AE, Lien HH, Paus E, Kaalhus O (1989) Histology of Tumor Residuals Following Chemotherapy in Patients with Advanced Nonseminomatous Testicular Cancer. J Urol 142: 1239–1242

    PubMed  CAS  Google Scholar 

  39. Levitt MD, Reynolds PM, Sheiner HJ, Byrne MJ (1985) Non-seminomatous germ cell testicular toumours: residual masses after chemotherapy. Br J Surg 72: 19–22

    Article  PubMed  CAS  Google Scholar 

  40. Fossa SD, Ous S, Lien HH, Stenwig AE: Post-Chemotherapy Lymph Node Histology in Radiologically Normal Patients With Metastatic Nonseminomatous Testicular Cancer. J Urol 141: 557–559

    Google Scholar 

  41. Donohue JP, Rowland RG, Kopecky K, Steidle ChP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P (1987) Correlation of Computerized Tomographic Changes and Histological Findings in 80 Patients Having Radical Retroperitoneal Lymph Node Dissection after Chemotherapy for Testis Cancer. J Urol 137: 1176–1179

    PubMed  CAS  Google Scholar 

  42. Toner GC, Herr HW, Panicek DM, Heelan RT, Geller NL, Lin SY, Whitmore WF, Fair WR, Morse MJ, Sogani PC, Bosl GJ (1990) Patients Selection For Retroperitoneal Lymph Node Dissection After Chemotherapy For Nonseminomatous Germ Cell Tumors. J Urol AUA, Abstract No 828

    Google Scholar 

  43. Murphy BR, Roth BJ, Foster RS, Bihrle R, Rowland RG, Messemer J, Sc B, Wahle G, Einhorn LH, Donohue JP (1993) Surgical salvage of chemorefractory germ cell tumors. J Urol 149: 454A — AUA Abstract No 967

    Google Scholar 

  44. Kührer I, Kratzik C, Wiltschke C (1991) Single Agent Carboplatin for Stage I Seminoma. Onkologie 14, Suppl 4: 23

    Google Scholar 

  45. Oliver RTD (1991) A comparison of the biology and prognosis of seminoma and non-seminoma. In: Horwich A (ed) Testicular cancer. Investigation and management. Chapman & Hall Medical, London-New York, pp 51–67

    Google Scholar 

  46. Horwich B, Dearnaley DP, Duchesne GM et al. (1989) Simple Nontoxic Treatment of Advanced Metastatic Seminoma With Carboplatin. J Clin Oncol 7: 11501156

    Google Scholar 

  47. Horwich A, Dearnaley D, Mason M, A Hearn R (1991) Single agent carboplatin for advanced seminoma. Proc Am Soc Clin Oncol 10: Abstract No 550

    Google Scholar 

  48. Schmoll HJ, Harstrick A, Bokemeyer C et al. (1993) Single agent Carboplatin for advanced seminoma. Cancer 72: 237–243

    Article  PubMed  CAS  Google Scholar 

  49. Clemm C, Hartenstein R, Willich N, Heim M, Wagner M, Williams W (1988) VIP-Chemotherapie beim Seminom mit großer Tumormasse. In: Schmoll HJ, Weißbach L (Hrsg) Diagnostik und Therapie von Hodentumoren. Springer, Berlin, S 461–467

    Google Scholar 

  50. Fossa SD, Borge L, Aass N et al. (1987) The treatment of advanced metastatic seminoma: Experience in 55 cases. J Clin Oncol 5: 1071–1077

    PubMed  CAS  Google Scholar 

  51. Sandeman TF, Yang C (1988) Results of Adjuvant Chemotherapy for Low-Stage Nonseminomatous Germ Cell Tumors of the Testis With Vascular Invasion. Cancer 62: 1417–1475

    Article  Google Scholar 

  52. Madej G, Pawinski A (1991) Risk-related adjuvant chemotherapy for stage I nonseminoma of the testis. Clin Oncol 3: 270–272

    Article  CAS  Google Scholar 

  53. Gonnermann D (1991) Primäre Chemotherapie beim Nichtseminom im Stadium I, Onkologie 14, Suppl 4: 14

    Google Scholar 

  54. Chevreau C, de Forni M, Soulie M Mihura J, Plante P (1991) Is adjuvant chemotherapy a beneficial treatment in stage I high non seminomatous testicular germ cell tumour? Eur J Cancer Suppl 2: Abstract No 651

    Google Scholar 

  55. Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW (1993) Adjuvant Chemotherapy after Orchiectomy in High-Risk Patients with Clinical Stage I Non-Seminomatous Testicular Cancer. Eur Urol 23: 444–449

    PubMed  CAS  Google Scholar 

  56. Cullen MH (1994) Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumours of the testis: An MRC Study Report. In: Germ Cell Tumours III (ed by Jones WG, Harden P, Appleyard I ), Elsevier Science Ltd Oxford New York Tokyo, p 201–202

    Google Scholar 

  57. Pont J, Albrecht W, Höltl W (1994) NSGCT Stage 1— Adjuvant chemotherapy for patients with vascular invasion and surveillance for patients without vascular invasion: Update of a prospective Trial after 8 years. In: Germ Cell Tumours III (ed by Jones WG, Harden P, Appleyard I ), Elsevier Science Ltd Oxford New York Tokyo, pp 207–208

    Google Scholar 

  58. Oliver RTD, Raja MA, Ong J, Gallagher CJ (1992) Pilot Study to Evaluate Impact of a Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer Patients. J Urol 148: 1453–1456

    PubMed  CAS  Google Scholar 

  59. Weißbach L, Hartlapp HJ (1991) Adjuvant chemotherapy of metastatic stage II non-seminomatous testis tumor. J Urol 146: 1295–1298

    PubMed  Google Scholar 

  60. Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1488

    Article  PubMed  CAS  Google Scholar 

  61. Williams SD, Birch R, Einhorn LH et al. (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440

    Article  PubMed  CAS  Google Scholar 

  62. Stoter G, Kaye S, Jones W et al. (1987) Cisplatin and Vp 16 ± Bleomycin (BEP vs EP) in good risk patients with disseminated non-seminomatous testicular cancer; results of a randomized EORTC-GU group study. Proc ECCO P 179: Abstract No 681

    Google Scholar 

  63. Einhorn LH, Williams SD, Loehrer PJ et al. (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a southeastern cancer study group protocol. J Clin Oncol 7: 387–391

    PubMed  CAS  Google Scholar 

  64. Bajorin DF, Sarosdy MF, Pfister DG et al. (1993) Randomized trial of etoposide and carboplatin in patients with good risk germ cell tumours. A multiinstitutional study. J Clin Oncol 11: 598–606

    PubMed  CAS  Google Scholar 

  65. Loehrer PJ, Elson P, Johnson DH et al. (1991) A randomized trial of cisplatin plus etoposide with or without bleomycin in favorable prognosis disseminated germ cell tumors: an ECOG study. Proc Am Soc Clin Oncol 10: Abstract No 540

    Google Scholar 

  66. Ozols RF, Ihde DC, Linehan WM et al. (1988) A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis non-seminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040

    PubMed  CAS  Google Scholar 

  67. Nichols CR, Williams SD, Loehrer PJ et al. (1991) Randomized study of cisplatin dose intensity in advanced germ cell tumors. A Southeastern and Southwest Oncology Group Protocol. J Clin Oncol 9: 1163–1172

    PubMed  CAS  Google Scholar 

  68. Loehrer PJ, Einhorn LH, Elson P, Williams SD, Havlin K, Vogelzang NJ, Crawford ED, Trump DL (1993) Phase III study of cisplatin plus etoposide with either bleomycin of ifosfamide in advanced stage germ cell tumors: an intergroup trial. Proc Am Soc Clin Oncol 12:261 — Abstract No 831

    Google Scholar 

  69. Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, Heron JF, Chevallier B, Fargeot P, Kramar A, Bouzy J (1993) Early Intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk nonseminomatous germ cell tumours. Preliminary results of a french randomized trial-Eur Urol 23: 213–218

    CAS  Google Scholar 

  70. Loehrer PJ, Einhorn LH, Williams SD et al. (1986) VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4: 528–536

    PubMed  Google Scholar 

  71. Harstrick A, Schmoll HJ, Wilke H et al. (1991) Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9: 1549–1555

    PubMed  CAS  Google Scholar 

  72. Ghosn M, Droz JP, Theodore C et al. (1988) Salvage chemotherapy in refractory germ cell tumors with etoposide plus ifosfamide plus high-dose cisplatin. Cancer 62: 24–27

    Article  PubMed  CAS  Google Scholar 

  73. Munshi NC, Loehrer PJ, Roth BJ et al. (1990) Vinblastine, ifosfamide and cisplatin as second line chemotherapy in metastatic germ cell tumors. Proc Am Soc Clin Oncol 9: Abstract No 520

    Google Scholar 

  74. Nichols CR, Tricot G, Williams SD et al. (1989) Dose intensive chemotherapy in refractory germ cell cancer — A phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932939

    Google Scholar 

  75. Nichols CR, Andersen J, Lazarus HM et al. (1992) High-dose carboplatin and etoposide with autologus bone marrow transplantation in refractory germ cell cancer. An Eastern Cooperative Oncology Group protocol. J Clin Oncol 72: 237–243

    Google Scholar 

  76. Linkesch W, Krainer M, Wagner A (1992) Phase I/II trial of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 11: Abstract No 600

    Google Scholar 

  77. Broun ER, Nichols CR, Turns M, Einhorn LH (1993) First line salvage therapy with conventional dose induction therapy and high dose chemotherapy with autologous bone marrow rescue for germ cell cancer. Proc Am Soc Clin Oncol 12: Abstract No 702

    Google Scholar 

  78. Siegert W, Beyer J, Strohscheer I et al. (1994) High dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell cancers. A phase I/II study. J Clin Oncol 12: 1223–1231

    PubMed  CAS  Google Scholar 

  79. Dieckmann KP, Besserer A, Loy V (1993) Low-dose radiotherapy for testicular intraepithelial neoplasia (Carcinoma in situ testis) — J Urol 149:454A — AUA Abstract No 964

    Google Scholar 

  80. Giwercman A, von der Maase H, Berthelsen JG, Rorth M, Bertelsen A, Skakkebaek NE (1991) Localized irradiation of testes with carcinoma in situ: Effects on leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 73: 596

    Article  PubMed  CAS  Google Scholar 

  81. Bussar-Maatz R, Weißbach L (1994) Prognosis of the HCG positive Seminoma. J Cancer Res Clin Oncol, Suppl 120: 65

    Google Scholar 

  82. Schmidberger H, Bamberg M, Schorcht J, Souchon R, Walter F, Born H, Flink MA (1994) Radiotherapy in Stage I, IIA and IIB Seminoma Testis. J Cancer Res Clin Oncol, Suppl 120: 66

    Google Scholar 

  83. Clemm Ch, Gerl A, Wendt TG, Pollinger B, Winkler PA, Wilmanns W (1993) Derzeitiger Stand der Therapie von ZNS-Metastasen bei Keimzelltumoren. Urologe A 32: 217–224

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. L. . Weißbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Harstrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Bussar-Maatz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weißbach, L..., Harstrick, A., Bussar-Maatz, R. (1995). Hodentumoren. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation